NASDAQ:ADMA
Adma Biologics, Inc.
Adma Biologics, Inc.'s revenue grew 19.6% in fiscal 2025 to $510.2M while operating margin rose to 37.5%, its highest in 10 years. Free cash flow was $27.8M, 5.5% of revenue, and the diluted share count rose 0.6%.Summary generated from Adma Biologics, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$510.2M
Revenue growth+19.6%
Revenue, 5-yr CAGR+64.6%
Gross margin57.4%
Operating margin37.5%
Net margin28.8%
ROIC39.5%
Return on equity35.6%
Debt / equity0.15
Free cash flow$27.8M
FCF margin5.5%
Share count change+0.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 81 | 154 | 258 | 426 | 510 |
| Operating income | −58 | −39 | 22 | 139 | 191 |
| Net income | −72 | −66 | −28 | 198 | 147 |
| Free cash flow | −126 | −73 | 4 | 110 | 28 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 4Insider transaction report
Jul 28, 2026 - 4Insider transaction report
Jul 17, 2026 - 8-KResults of a shareholder vote
Jun 2, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - 8-KOther events
May 4, 2026